The patent battle between Warner-Lambert (Pfizer) and Actavis and Mylan reached the Supreme Court in February 2018. Members of Fieldfisher's patent litigation team were in court to hear the judges' initial reaction to the arguments which can shed light on where the court's reasoned judgment will end up. The issues are of huge significance to users of the patent system. They include whether a patentable invention needs to be made "plausible" at the filing date and, if so, the level of information the patent application must include, and the correct approach to enforcing second medical use claims.
Supreme Court poised to hear another landmark patent case – with an ever increasing number of interveners
Hot on the heels of its ground breaking decision last summer in Actavis UK Ltd v Eli Lilly & Co  UKSC 48, which introduced a doctrine of equivalents into English law, the Supreme Court is poised to hear another very significant patent case, Warner-Lambert v Actavis, this month, as we report in this blog.